Result: Risk Minimisation Materials for medicines starting with the letter L
Lariam
Cheplapharm Arzneimittel GmbH

Checklist for the prescription, supply or recommendation of Lariam® (mefloquine) for malaria chemoprophylaxis
This educational material is provided by Neon Healthcare Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.
For Healthcare Professionals

Lariam (mefloquine) Guide for Healthcare Professionals
This educational material is provided by Neon Healthcare Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.
For Healthcare Professionals

Lariam (mefloquine) Patient Alert Card
This educational material is provided by Neon Healthcare Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.
Leflunomide
medac GmbH

Leflunomide medac - RMP Patient Leaflet
Risk Management Educational Material

Leflunomide medac - RMP Physician Leaflet
In addition to the Summary of Product Characteristics, this leaflet was developed by the marketing authorisation holder to inform you about all delicate issues potentially arising from Leflunomide medac therapy. Counselling patients on important risks associated with Leflunomide medac therapy and appropriate precautions when using the medicine is required.
For Healthcare Professionals
Mylan

Leflunomide Physician Leaflet
This leaflet is to highlight the most important risks associated with Leflunomide and to emphasize the need for counselling patients about those important risks
For Healthcare Professionals
Tillomed Laboratories Ltd

Leflunomide Tillomed 10mg & 20mg Tablets - Guide for Patients
Guide for Patients

Leflunomide Tillomed 10mg & 20mg Tablets - Prescriber's Guide
Prescriber's Guide
For Healthcare Professionals
Lemtrada
Sanofi Genzyme

Lemtrada (alemtuzumab) - Healthcare Professional (HCP) Guide - Risk Minimisation Information for Healthcare Professionals
This guide has been developed for prescribers and healthcare professionals (HCPs) involved in the care of patients treated with Lemtrada (alemtuzumab), to provide further information about the potential serious risks associated with the use of this medicine. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals

Lemtrada (alemtuzumab) - Patient Alert Card - Risk Minimisation Information for Patients
The card should be provided to patients prior to treatment by the prescribing physician and is designed to alert other HCPs that the patient has been prescribed Lemtrada (alemtuzumab) and includes details on the associated risks of treatment and contact details of the prescriber. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Lemtrada (alemtuzumab) - Patient Guide - Risk Minimisation Information for Patients
The guide should be provided to patients prior to treatment by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring including your doctors contact details and an overview of treatment monitoring. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Lemtrada (alemtuzumab) – Prescriber check list - Risk Minimisation Information for Healthcare Professionals
Describes required initial screening tests, pre-treatment vaccination course, premedication, general health, and pregnancy and contraception checks immediately before treatment and the subsequent monitoring activities. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals
Levest
Morningside Healthcare Ltd

Checklist for Prescribers - Levest
Please use this checklist in conjunction with the SPC during combined hormonal contraceptives consultations. Risk of Thromboembolism.
For Healthcare Professionals

Important Information for Women - Levest Tablets
This is a bit more information about the recommendations of combined hormonal contraceptives, in particular the risk of blood clots. Includes key points to bear in mind.

Patient Card - Levest
Important information for women about the risk of blood clots with the combined hormonal contraceptives.
Levetiracetam
Aurobindo Pharma - Milpharm Ltd.

Levetiracetam oral solution - Risk of medication errors associated with overdose
Levetiracetam overdose can lead to serious adverse event. With every prescription, physicians and pharmacists should advise the patient and/or caregiver on how to measure the prescribed dose
For Healthcare Professionals
Levobunolol
Aspire Pharma Ltd

Dispensing guide
An aide-mémoire for pharmacists dispensing Librachrom to ensure the unique features of the product are explained to patients.
Levonelle
Bayer plc

Levonelle One Step Patient Questionnaire Checklist
Instructions for Pharmacists supplying Levonelle One Step 1500 microgram tablet as emergency contraception
For Healthcare Professionals

Levonorgestrel Patient Sheet
Levonorgestrel emergency contraception: important information for women taking other medicines
Levonorgestrel
Lupin Healthcare (UK) Ltd

Advice for women taking Levonorgestrel tablets
Advice for women taking Levonorgestrel tablets Levonorgestrel 1.5mg Tabletsl PL35507-0126

Checklist for Pharmacists
Checklist for Pharmacists Levonorgestrel 1.5mg Tablets PL 35507-0126

Levonorgestrel Patient Sheet
Levonorgestrel emergency contraception: important information for women taking other medicines. Some medicines or herbal remedies that contain the ingredient St. John's wort, might reduce how well levonorgestrel emergency contraception works. Tell the doctor, pharmacist or nurse if you are currently taking a medicine to treat any of the following, or if you have used one in the past 4 weeks: epilepsy, tuberculosis, HIV, a fungal infection, or if you have taken any herbal remedies that contain the ingredient St. John's wort.
Mylan

Educational material for Pharmacists & Patients
Checklist for Pharmacists and Patients
Gedeon Richter (UK) Ltd

Emergency Contraceptive Richter 1500mcg Patient Questionnaire checklist
Instructions for Pharmacists supplying Emergency Contraceptive Richter 1500 microgram tablet as emergency contraception
For Healthcare Professionals

Levonorgestrel Patient Sheet
Levonorgestrel emergency contraception: important information for women taking other medicines.
THE BOOTS COMPANY PLC

Levonorgestrel Patient Sheet
Levonogestrel emergency contraception: important information for women taking other medicines.
Levosert
Gedeon Richter (UK) Ltd

Levosert HCP educational brochure
This educational brochure is intended to minimise the risk of medication errors due to confusion between Levosert and other available LNG IUS and to provide information on the risk of ectopic pregnancies in women using Levosert.
For Healthcare Professionals

Libtayo
SANOFI

Libtayo-Patient Alert Card- Patients treated with cemiplimab
This Patient Alert Card will help you identify and report any symptoms of side effects from your treatment with cemiplimab. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Libtayo-Patient Guide- Patients treated with cemiplimab
This Patient Guide will help you identify and report any symptoms of side effects from your treatment with cemiplimab. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
Lixiana
Daiichi Sankyo UK Limited

Lixiana (edoxaban) Patient Alert Card
Every patient prescribed Lixiana will receive a Patient Alert Card in the medication pack. This will inform doctors, dentists, pharmacists and other healthcare professionals about the patient’s anticoagulation treatment, along with emergency contact details. Encourage patients to have this card with them at all times and to show it to healthcare professionals prior to any consultation or procedure. Patients should be reminded of the importance of compliance to their treatment regimen, the need to watch for signs and symptoms of bleeding and when to seek medical advice. Patient Alert Cards are available from [email protected] or by calling 08000285122.

Lixiana (edoxaban) Prescriber Guide
This risk minimisation material has been developed for Lixiana for all indications. Please ensure that you are familiar with this material as it contains important safety information. In particular, it is aimed at increasing awareness about the potential risk of bleeding during treatment with Lixiana and providing guidance on how to manage that risk.
For Healthcare Professionals
Lizinna
Morningside Healthcare Ltd

Checklist for Prescribers - Lizinna
Please use this checklist in conjunction with the SPC during combined hormonal contraceptives consultations. Risk of thromboembolism.
For Healthcare Professionals

Important Information for Women - Lizinna
This is more information on recommendations of safety of combined hormonal contraceptives, in particular the risk of blood clots.

Patient Card - Lizinna
Important Information for women about risk of blood clots with combined hormonal contraceptives.
Logynon
Bayer plc

CHCs - Checklist for Prescribers
Combined Hormonal Contraceptives - checklist for prescribers
For Healthcare Professionals

CHCs - Q&A on Important Info for Women
Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs
Important Information for women about risk of blood clots with combined hormonal contraceptives.
Logynon ED
Bayer plc

CHCs - Checklist for Prescribers
Combined Hormonal Contraceptives - checklist for prescribers
For Healthcare Professionals

CHCs - Q&A on Important Info for Women
Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs
Important Information for women about risk of blood clots with combined hormonal contraceptives.
Lojuxta
Amryt Pharmaceuticals DAC

Lojuxta (lomitapide) Healthcare Professional Guide
Healthcare professional guide contains information on the serious risks associated with Lojuxta and how to help mitigate these risks.
For Healthcare Professionals

Lojuxta Alert Card
The purpose of the patient alert card is to inform health care professionals of potential drug-drug interactions before any additional medicinal product is taken. Patients will be instructed to carry this card and show it to all doctors and pharmacists involved in their treatment.

Lojuxta Patient Care Guide
Patient care guide containing important safety information for patients treated with Lojuxta (lomitapide).
Losartan+Hydrochlorothiazide
Mylan

Direct HCP Communication: Hydrochlorothiazide, risk of non‐melanoma skin cancer
Direct Healthcare Professional Communication Hydrochlorothiazide: Risk of non‐melanoma skin cancer
For Healthcare Professionals
Aurobindo Pharma - Milpharm Ltd.

Losartan/HCTZ- HCP letter- Hydrochlorothiazide and the risk of non-melanoma skin cancer
The prescriber should inform the patients taking hydrochlorothiazide (HCTZ) containing medicines of the risk of non-melanoma skin cancer. Patients should be advised to limit the exposure to sunlight and UV rays and use adequate protection when exposed to sunlight and UV rays to minimise the risk of skin cancer
For Healthcare Professionals
Lucentis
Novartis Pharmaceuticals UK Ltd

Lucentis (ranibizumab) - Patient information booklet (AMD) - for patients
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD). An audio version is available on eMC.

Lucentis (ranibizumab) - Patient information booklet (CNV) - for patients
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV)secondary to pathological myopia. An audio version is available on eMC.

Lucentis (ranibizumab) - Patient information booklet (DMO/PDR) - for patients
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO). An audio version is available on eMC.

Lucentis (ranibizumab) - Patient information booklet (RVO) - for patients
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to retinal vein occlusion (RVO). An audio version is available on eMC.
Luxturna
Novartis Pharmaceuticals UK Ltd

Luxturna (voretigene neparvovec) - Patient Alert card - for Patients
Patient card to track treatment and provide useful contact details

Luxturna (voretigene neparvovec) - Patient information leaflet A4 - for Patients
Patient information leaflet size A4

Luxturna (voretigene neparvovec) - Pharmacy training material - for Healthcare Professionals
Pharmacy manual for dose preparation of Luxturna
For Healthcare Professionals

Luxturna (voretigene neparvovec) - Surgical training material - for Healthcare Professionals
Surgical manual for the administration of Luxturna
For Healthcare Professionals
Lynparza
AstraZeneca UK Limited

Lynparza Dear Healthcare Professional Communication
To reduce the risk of medication errors with the new tablet pharmaceutical form.
For Healthcare Professionals

Lynparza Dear Healthcare Professional Communication
Lynparza Dear Healthcare Professional Communication
For Healthcare Professionals

Lynparza Dear Healthcare Professional Communication
To reduce the risk of medication errors with the new tablet pharmaceutical form.
For Healthcare Professionals